C4 Therapeutics (CCCC) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 63.3% versus a gain of 24.8%. Over five years, RLMD leads with a -86.2% price change compared with -93.6% for CCCC. C4 Therapeutics is the larger company by market cap ($346.9 million vs $346.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | RLMD |
|---|---|---|
| Share price | $2.82 | $3.25 |
| Market cap | $346.93M | $346.68M |
| 1-day change | -2.08% | -0.91% |
| YTD return | +47.64% | -32.71% |
| 1-year return | +24.78% | +63.32% |
| 5-year return | -93.57% | -86.25% |
| EPS (TTM) | $-0.91 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $8.00 |
| 52-week low | $1.69 | $1.80 |
| Distance from 52-week high | -45.45% | -59.38% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +372.70% | +230.77% |
| Average volume | 2.39M | 1.34M |
| Shares outstanding | 123.03M | 106.67M |
| Employees | 104 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed CCCC by 38.5 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 17 employees
CCCC vs RLMD FAQ
Which is bigger, C4 Therapeutics or Relmada Therapeutics?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $346.93M compared with $346.68M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, CCCC or RLMD?
RLMD returned +63.32% over the past 12 months, compared with +24.78% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.